This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A new study provides a list of the wildlife species present at the market from which SARS-CoV-2, the virus responsible for the COVID-19 pandemic, most likely arose in late 2019. The study is based on a new analysis of metatranscriptomic data released by the Chinese Center for Disease Control and Prevention (CDC).
1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).
Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.
Experts believe brain-related effects may be tied to the body’s immune response to the virus and possibly to vascular problems or surges of inflammation caused by the disease. WHO is working with scientists around the world to “better understand any and all changes to the virus” and their impact, he said.
In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a highly contagious and pathogenic virus, made its alarming debut and quickly spread worldwide, causing the novel coronavirus (COVID-19) pandemic that threatened human health and public safety.
In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The role of extracellular vesicles in COVID-19 virus infection [Internet]. Available from: [link]
27, 2020 /PRNewswire/ — Aridis Pharmaceuticals, Inc. Dr. Hasan Jafri , Chief Medical Officer of Aridis Pharmaceuticals, will be a speaker on a panel entitled “Direct Antivirals and Other Agents Against SARS-CoV2 Virus.” SAN JOSE, Calif. , AR-711 (COVID-19). AR-201 (RSV infection). AR-201 (RSV infection).
A new survey shows one in five cancer patients are far less likely to participate in future clinical trials due to fear of COVID-19 exposure, raising the question of whether enrollment levels that have dropped precipitously since the beginning of the pandemic are likely to recover after the virus is controlled. percent since March 15.
29, 2020– Alexion Pharmaceuticals, Inc. NASDAQ:ALXN) today announced financial results for the third quarter of 2020. Non-GAAP diluted EPS for the third quarter of 2020 was $3.24 , a 16 percent increase versus the third quarter of 2019. ” Third Quarter 2020 Financial Highlights. in the prior year.
22, 2020 (GLOBE NEWSWIRE) — Replimune Group, Inc. The offering is expected to close on October 26, 2020, subject to the satisfaction of customary closing conditions. BOSTON, Oct. Morgan Securities LLC, SVB Leerink LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering.
This donation of the vaccine is another tool in our toolbox of measures to help make the Olympic and Paralympic Games Tokyo 2020 safe and secure for all participants and to show solidarity with our gracious Japanese hosts,” said IOC President Thomas Bach. “We This press release features multimedia. View the full release here: [link].
S is derived from a common cold virus that is modified to carry a gene from the SARS-CoV-2 virus which causes COVID-19, prompting the immune system to develop resistance to the virus.
Because SARS-CoV-2 is so highly infectious, basic researchers without access to specially designed biosafety facilities may be limited in their ability to study the virus. While the quantum dots may bind and enter human cells just like the virus, they can’t cause an infection. 2020 Sep 22;14(9):12234-12247.
The announcement, following a $98 million IPO in October 2020, comes as the company advances several programs through its pipeline. In addition to its lead program, which began Phase I testing in 2020, the company expects to nominate three clinical candidates in 2021.
10, 2020 04:32 UTC. The offering is expected to close on or about December 14, 2020, subject to satisfaction of customary closing conditions. Rocket’s first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Forward-looking Statements.
28, 2020 — Travelers flying to the United States from the United Kingdom will now need a negative COVID-19 test no more than 72 hours before leaving Britain, the U.S. The test is needed to guard against the spread of a new form of the virus found in the United Kingdom that may be 70 percent more contagious than other forms of COVID-19.
While the overall understanding of the condition is as novel as the virus that causes it, a recent survey from the U.K.’s This is proving very difficult, however, for the ever-expanding group of people dealing with the chronic and debilitating symptoms of what is commonly being called “Long Haul COVID” or “Long COVID.”.
The outcome confirms that only one single case was attributable to the original SARS-CoV-2 virus. “In addition, the variant-rich environment underlines the importance of developing next-generation vaccines as new virus variants continue to emerge.” More than half of the cases (57%) were caused by Variants of Concern.
> I sometimes wonder what percentage of the pharmacopoeia will have been proposed for repurposing for the treatment of COVID19 by the end of 2020. There are three general approaches to directly tackle a virus such as SARS-CoV-2 with a small molecule drug (or chemical agent).
3, 2020 09:00 UTC. MTX-COVAB was also found to have virus neutralizing potency (IC50= 40pM), which is comparable or better to that of the leading antibody therapies in development, and cross-neutralizes all clinically relevant virus mutants. About Memo Therapeutics AG.
28, 2020 /PRNewswire/ — . In the overall patient group with detectable virus at baseline, the average daily reduction in viral load through day 7 was a 0.36 Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2019 and its Form 10-Q for the quarterly period ended June 30, 2020.
Date: 7 December 2020 . WHO-identifier: 2020/5, version 1. The design principle of RT-PCR means that for patients with high levels of circulating virus (viral load), relatively few cycles will be needed to detect virus and so the Ct value will be low.
He said the company will potentially supply 76 million doses of the plant-based vaccine, which uses noninfectious virus-like particles to mimic the coronavirus in order to induce an immune response. The interim analysis from the phase 1 trial has been published online at the preprint server, medRxiv. Martin Berman-Gorvine.
The analysis included 945,941 mRNA participants (778,534 with two doses), 426,272 Vaxzevria participants, conducted between 27 December 2020 and 19 May 2021. After vaccination, the surface spike protein is produced, priming the immune system to attack the SARS-CoV-2 virus if it later infects the body.
The two companies have collaborated for more than 20 years to rapidly address critical healthcare needs including biological threats, such as SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus and most recently, SARS-CoV-2 virus and its variants.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content